One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...

New AI chatbot called Ash is different, Slingshot founders say, because its training model is based on real therapeutic ...

Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the market, a senior FDA official told STAT.

Join Bill Gates and a range of experts for a discussion on flattening barriers to improving women’s health — from research ...

The crisis over Sarepta Therapeutics' Duchenne therapy offers a valuable lesson: Listening to critics, and responding with ...

Worsening a patient's credit can prevent them from getting a job, renting an apartment, or even paying their outstanding ...

Humana has refiled its lawsuit against the federal government over its Medicare Advantage ratings, with billions of dollars ...

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...